GMAB Genmab A/S ADS Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
17:51
Jul 14
Jul 14
The author is compiling a list of follower-requested stocks for future review without expressing any current positions or trade ideas.
LOW
07:31
Jul 05
Jul 05
The author lists 23 stocks he plans to review after receiving suggestions from followers, with no current position or directional view expressed.
LOW
11:33
Jun 30
Jun 30
Pre-market movers include Apple and Google flat on UK CMA probe, CNXC plunging 24% on weak outlook, DLR falling 5% on data center deal, AVAV surging 28% on earnings beat, GMAB rising 8% on positive trial results, ABBV and MRK dipping on House investigation, and LCII up 7% on merger with Patrick Industries.
20:39
Jun 08
Jun 08
Ticker mentioned as a reminder in a GLP-1 discussion, no directional view or catalyst stated.
LOW
17:30
Jun 02
Jun 02
The author disagrees with an M&A hypothesis for ABVX by citing GMAB's acquisition of Merus during phase 3 as a counterexample, but does not state a personal position.
LOW
22:01
Jun 01
Jun 01
Notes GMAB receives ~15% royalties from JNJ's Darzalex, a key revenue driver for the company.
LOW
14:27
May 12
May 12
Long $GMAB (Genmab) — paired with HALO as a Darzalex revenue capture play; speaker holds both as siphons on Darzalex sales.
MED
04:28
Feb 17
Feb 17
A sell-side analyst is initiating coverage on GMAB with a price target, indicating a bullish forward-looking view on the stock.
MED
About GMAB Analyst Coverage
Buzzberg tracks GMAB (Genmab A/S ADS) across 4 sources. 1 bullish vs 0 bearish calls from 4 analysts. Sentiment: predominantly bullish (12%). 8 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: __con_, Newsquawk, frenchv33921.